ImpediMed (IPD) Stock Overview
A medical technology company, develops, manufactures and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
IPD Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
ImpediMed Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.037 |
| 52 Week High | AU$0.06 |
| 52 Week Low | AU$0.026 |
| Beta | 1.53 |
| 1 Month Change | -9.76% |
| 3 Month Change | -7.50% |
| 1 Year Change | -30.19% |
| 3 Year Change | -61.05% |
| 5 Year Change | -72.59% |
| Change since IPO | -95.65% |
Recent News & Updates
Recent updates
We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth
Jun 26
ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans
Mar 05Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth
Nov 23Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?
Jul 11We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully
Mar 27Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation
Sep 28Shareholder Returns
| IPD | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | -2.3% |
| 1Y | -30.2% | -3.7% | 3.9% |
Return vs Industry: IPD underperformed the Australian Medical Equipment industry which returned -3.7% over the past year.
Return vs Market: IPD underperformed the Australian Market which returned 3.9% over the past year.
Price Volatility
| IPD volatility | |
|---|---|
| IPD Average Weekly Movement | 13.0% |
| Medical Equipment Industry Average Movement | 11.5% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in AU Market | 19.5% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: IPD has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: IPD's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 77 | Parmjot Bains | www.impedimed.com |
ImpediMed Limited, a medical technology company, develops, manufactures and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-care body composition analysis; and HF-Dex analysis for point-of-care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications.
ImpediMed Limited Fundamentals Summary
| IPD fundamental statistics | |
|---|---|
| Market cap | AU$75.34m |
| Earnings (TTM) | -AU$23.24m |
| Revenue (TTM) | AU$12.72m |
Is IPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPD income statement (TTM) | |
|---|---|
| Revenue | AU$12.72m |
| Cost of Revenue | AU$1.75m |
| Gross Profit | AU$10.98m |
| Other Expenses | AU$34.21m |
| Earnings | -AU$23.24m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.011 |
| Gross Margin | 86.25% |
| Net Profit Margin | -182.62% |
| Debt/Equity Ratio | 67.3% |
How did IPD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/18 00:05 |
| End of Day Share Price | 2025/11/18 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImpediMed Limited is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shane Storey | Canaccord Genuity |
| Scott Power | Morgans Financial Limited |
| Thomas Godfrey | Ord Minnett Limited |